Physician profile
Heather King
NPI 1689298499
$3,618.28
in general payments reported to CMS, 2019-2025
23 companies · $19.59 in 2025
The $19.59 reported for 2025 was less than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $765 · 2022: $1,064 · 2023: $1,038 · 2024: $732 · 2025: $19.59.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,790.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,789.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $682.68 | 2021-2025 | |
| Bausch Health US, LLC | $637.30 | 2021-2024 | Aplenzin, Wellbutrin |
| Supernus Pharmaceuticals, INC. | $428.36 | 2021-2024 | Qelbree, Qelbree |
| Alkermes, INC. | $416.37 | 2021-2024 | Lybalvi, Aristada, Vivitrol |
| Lundbeck LLC | $184.57 | 2021-2023 | Rexulti |
| Neurocrine Biosciences, INC. | $155.58 | 2021-2023 | Ingrezza |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $124.23 | 2021-2024 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $122.29 | 2021-2023 | Rexulti, Abilify Asimtufii |
| Neos Therapeutics, LP | $107.44 | 2021-2022 | |
| Ironshore Pharmaceuticals INC. | $101.22 | 2022-2024 | Jornay Pm |
| Corium, LLC | $97.74 | 2021-2024 | Azstarys |
| Janssen Pharmaceuticals, INC | $89.33 | 2021-2024 | Spravato |
| Tris Pharma INC | $82.09 | 2022-2024 | Dyanavel Xr |
| Takeda Pharmaceuticals U.S.A., INC. | $79.43 | 2021-2022 | |
| Vanda Pharmaceuticals INC. | $73.53 | 2021-2023 | Hetlioz, Fanapt |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Noven Therapeutics, LLC | $56.36 | 2023-2024 | Xelstrym |
| Axsome Therapeutics, INC. | $52.74 | 2023 | Auvelity |
| Idorsia Pharmaceuticals US INC | $40.42 | 2023-2024 | Quviviq |
| Scpharmaceuticals INC. | $19.69 | 2024 | |
| Glaxosmithkline, LLC. | $18.27 | 2021 | |
| Aytu Biopharma, INC. | $18.17 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $17.29 | 2022 | |
| Next Science LLC | $13.18 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Heather King listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.